MICSI makes software that sharpens MRI scans using a mathematical noise-removal method. Its first product is FDA cleared, and the company applies it to prostate cancer imaging and to planning brain tumour surgery.
Microstructure Imaging, Inc. (MICSI) develops physics-based imaging software for existing MRI and PET scanners. Its first product, MICSI-RMT, uses random matrix theory (MP-PCA) denoising and received FDA 510(k) clearance (K241121) on 17 July 2024 for MRI image enhancement; a PET product has been submitted. The company's site presents prostate diffusion MRI, including detection of low-grade prostate cancer, and brain imaging as use cases, and its chief executive Gregory Lemberskiy and chief technology officer Benjamin Aron trained at NYU. In fiscal year 2026 NCI awarded it USD 1,137,424 under SBIR award 2R44CA257624-02 for non-invasive neurosurgical planning in brain tumours with random matrix theory MRI.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 2R44CA257624-02: Non-invasive neurosurgical planning with Random Matrix Theory MRI | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
MICSI-RMT is FDA-cleared software from MICSI that cleans noise out of MRI scans. It is used on brain and prostate scans, including to look for prostate cancer and to plan brain tumour surgery.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/